Dermata Therapeutics Inc (DRMA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.06M
Last updated: Nov 17, 2026 at 4:10 PM ET
Dermata Therapeutics Inc (DRMA) Statistics
Dermata Therapeutics (DRMA) has a market cap of $3.06M. It kept -12811.49% of revenue as net income over the last 12 months. Its share count is up 398.76% from a year earlier.
Total Valuation
| Market Cap | $3.06M |
|---|---|
| Latest price (Nov 17, 2026) | $0.57 |
Key Dates
The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 39.4x and 0.7x.
| P/S Ratio | 39.4x |
|---|---|
| Forward P/S | 30.6x |
| P/B Ratio | 0.7x |
Price Statistics
The stock is down 81.43% over 52 weeks and trades 39.36% below its 50-day average.
| Beta (1Y) | 1.22 |
|---|---|
| 52-Week Change | -81.43% |
| 1-Month Change | -33.70% |
| 3-Month Change | -61.22% |
| 6-Month Change | -51.69% |
| 5-Year Change | -99.99% |
| Total Return (1Y) | -81.43% |
| Total Return (3Y CAGR) | -82.42% |
| Total Return (5Y CAGR) | -86.22% |
| Max Drawdown (1Y) | -81.84% |
| Max Drawdown (3Y) | -99.54% |
| Sharpe Ratio (1Y) | -1.23 |
| Correlation with SPY (1Y) | 0.13 |
| 50-Day Average | $0.94 |
| 200-Day Average | $1.22 |
| 52-Week Range | $0.57 to $3.16 |
| RSI (14 Days) | 30.7 |
| Average Volume (20 Days) | 102.59K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.36x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 2.36x |
|---|---|
| Quick Ratio | 2.05x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -243.17% and return on assets is -143.14% over the last 12 months.
| Return on Equity (ROE) | -243.17% |
|---|---|
| Return on Assets (ROA) | -143.14% |
| ROIC (5Y Average) | -96.74% |
| Asset Turnover | 0.01x |
| Inventory Turnover | 0.07x |
Scores
DRMA has an Altman Z-Score of -20.56, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -20.56 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $74.14K over the last 12 months.
| Revenue | $74.14K |
|---|---|
| Operating Income | -$9.70M |
| Pretax Income | -$9.50M |
| Net Income | -$9.50M |
| Reported EPS (TTM) | -$3.29 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 58.89% of the $6.64M in total assets.
| Cash and Equivalents | $4.82M |
|---|---|
| Total Debt | $0 |
| Net Cash | $4.82M |
| Net Cash Per Share | $0.94 |
| Working Capital | $3.70M |
| Shareholder Equity | $3.91M |
| Book Value Per Share | $0.76 |
| Total Assets | $6.64M |
| Total Liabilities | $2.73M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$8.88M |
|---|---|
| FCF Per Share | -$1.80 |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -13082.32%.
| Operating Margin | -13082.32% |
|---|---|
| Pretax Margin | -12811.49% |
| Net Margin | -12811.49% |
Dividends and Yields
DRMA does not pay a dividend.
| Buyback Yield | -322.14% |
|---|---|
| Shareholder Yield | -322.14% |
Stock Splits
The last split was a 1-for-10 reverse split on Aug 1, 2025.
| Last Split Date | Aug 1, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About DRMA
What is DRMA's market cap?
Dermata Therapeutics has a market cap of $3.06M.
How many shares of DRMA are outstanding?
Dermata Therapeutics has 5.12M shares outstanding. The count is up 398.76% from a year earlier.
Does DRMA pay a dividend?
No. Dermata Therapeutics does not pay a dividend.
How much debt does DRMA have?
Dermata Therapeutics has $0 of total debt and $4.82M of cash and equivalents, a net cash position of $4.82M.
DRMA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors